We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
InVivo Therapeutics Holdings Corporation | NASDAQ:NVIV | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.3207 | 0.2616 | 0.2679 | 0 | 01:00:00 |
|
Nevada
(State or other Jurisdiction of
Incorporation or Organization) |
| |
3841
(Primary Standard Industrial
Classification Code Number) |
| |
36-4528166
(I.R.S. Employer
Identification No.) |
|
| Large accelerated filer | | | ☐ | | | Accelerated filer | | | ☐ | |
| Non-accelerated filer | | | ☒ | | | Smaller reporting company | | | ☒ | |
| | | | | | | Emerging growth company | | | ☐ | |
| | | | | ii | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 11 | | | |
| | | | | 14 | | | |
| | | | | 16 | | | |
| | | | | 17 | | | |
| | | | | 18 | | | |
| | | | | 19 | | |
| | |
Shares of Common Stock
Owned Prior to Offering |
| |
Number of shares of
Common Stock to Being Offered |
| |
Shares of Common Stock
Owned After Offering(1) |
| |||||||||||||||||||||
Name of Selling Stockholder
|
| |
Number
|
| |
Percentage
|
| |
Number
|
| |
Percentage
|
| ||||||||||||||||||
Armistice Capital Master Fund, Ltd.(2)
|
| | | | 2,984,901 | | | | | | 60.5% | | | | | | 2,904,762 | | | | | | 80,139 | | | | | | 1.6% | | |
Michael Vasinkevich(3)(4)
|
| | | | 78,950 | | | | | | 1.6% | | | | | | 71,454 | | | | | | 7,496 | | | | | | 0.2% | | |
Noam Rubinstein(3)(5)
|
| | | | 54,139 | | | | | | 1.1% | | | | | | 35,100 | | | | | | 19,039 | | | | | | 0.4% | | |
Craig Schwabe(3)(6)
|
| | | | 4,136 | | | | | | 0.1% | | | | | | 3,761 | | | | | | 375 | | | | | | — | | |
Charles Worthman(3)(7)
|
| | | | 1,233 | | | | | | — | | | | | | 1,114 | | | | | | 119 | | | | | | — | | |
| | |
Amount to
be Paid |
| |||
SEC registration fee
|
| | | $ | 731.26 | | |
Printing fees and expenses
|
| | | | 10,000 | | |
Legal fees and expenses
|
| | | | 50,000 | | |
Accounting fees and expenses
|
| | | | 15,000 | | |
Total
|
| | | $ | 75,731.26 | | |
| | | |
By:
/s/ RICHARD TOSELLI
Richard Toselli
President and Chief Executive Officer (Principal Executive Officer) |
|
| | | |
By:
/s/ RICHARD CHRISTOPHER
Richard Christopher
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer) |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ RICHARD TOSELLI
Richard Toselli
|
| |
President and Chief Executive Officer (Principal Executive Officer) and Director
|
| |
November 8, 2022
|
|
|
/s/ RICHARD CHRISTOPHER
Richard Christopher
|
| |
Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)
|
| |
November 8, 2022
|
|
|
/s/ C. ANN MERRIFIELD
C. Ann Merrifield
|
| |
Director
|
| |
November 8, 2022
|
|
|
/s/ DANIEL R. MARSHAK
Daniel R. Marshak
|
| |
Director
|
| |
November 8, 2022
|
|
|
/s/ CHRISTINA MORRISON
Christina Morrison
|
| |
Director
|
| |
November 8, 2022
|
|
|
/s/ RICHARD ROBERTS
Richard J. Roberts
|
| |
Director
|
| |
November 8, 2022
|
|
|
/s/ ROBERT J. ROSENTHAL
Robert J. Rosenthal
|
| |
Director
|
| |
November 8, 2022
|
|
1 Year InVivo Therapeutics Chart |
1 Month InVivo Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions